Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-05 | Alfonso G. Zulueta Age 55 Director since 2018 Mr. Zulueta is Senior Vice President with Eli Lilly and Company and President of Lilly International. ... The Board has nominated Mr. Zulueta to serve on the Audit Committee following Mr. Catlow's retirement and Mr. Zulueta’s election at the 2018 Annual Meeting. |
| 2019-04-04 | Alfonso G. Zulueta Age 56 Director since 2018 ... Committee Membership Alfonso G. Zulueta: Audit Committee, Technology and Transactions Committee ... 2018 Director Compensation Alfonso G. Zulueta: Fees Earned or Paid in Cash $45,000, Stock Awards $121,170, Total $166,170 |
| 2020-04-02 | Alfonso G. Zulueta Age 57 Director since 2018 Committee Membership in 2019: Audit Committee, Compensation Committee 2019 Director Compensation: $182,364 total |
| 2021-04-01 | ALFONSO G. ZULUETA Age 58 Director since 2018 ... Senior Vice President of Eli Lilly and Company (2014 - Present) ... The Board believes that Mr. Zulueta’s broad global management experience ... Alfonso G. Zulueta 57,000 Fees Earned or Paid in Cash, 122,766 Stock Awards, 179,766 Total |
| 2022-04-01 | Nominee Alfonso G. Zulueta Age: 59 Director since: 2018 Professional Experience: President of Lilly International (2017–2021) Member of Executive Committee of Eli Lilly and Company (2014–2021) Senior Vice President of Eli Lilly and Company (2011–2021) President of Emerging Markets and various other roles with Eli Lilly and Company (1988–2014) Other Public Company Boards: Director of Syneos Health, Inc. (2022–Present) Committees of the Board of Directors: Audit Committee, Compensation Committee, Nominating, Governance and Sustainability Committee 2021 Director Compensation: $192,084 |
| 2023-03-31 | Mr. Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company (NYSE: LLY), a global pharmaceutical company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and, most recently, as President of International responsible for all geographies outside the United States and Canada, from 2017 until his retirement at the end of 2021. Mr. Zulueta also served as a corporate officer and a member of Eli Lilly and Company’s Executive Committee. Mr. Zulueta previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council. Mr. Zulueta currently serves on the Board of Directors of Amarin Corporation (NASDAQ: AMRN), a global biopharmaceutical company that specializes in medicines for the treatment of cardiovascular disease, where he is a member of the Compensation Committee. Mr. Zulueta also currently serves on the Board of Directors of Syneos Health, Inc. (NASDAQ: SYNH), an integrated biopharmaceutical services provider, where he is a member of the Nominating and Corporate Governance and Compensation Committees. The Board believes that Mr. Zulueta’s broad global management experience, his exposure to a range of cultures, and his deep experience in medical markets, make him well qualified to serve as a director. Committee Assignments: Audit, Nominating, Governance and Sustainability. 2022 Director Compensation: $201,874. |
| 2024-03-29 | Mr. Zulueta is a member of Audit and Nominating, Governance and Sustainability Committees. 2023 Director Compensation table shows total compensation of $209,723. |
| 2025-03-28 | Mr. Zulueta spent over three decades in various roles with Eli Lilly and Company. |
Data sourced from SEC filings. Last updated: 2025-06-20